NCT01747499

Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation

Phase I/II Trial of Intravenous Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 54 (actual)
• Sponsor: Washington University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this phase I/II study is to define the maximum tolerated dose of 5-AzaC and the effect on grade II-IV GvHD when given after matched unrelated donor transplant (MUD).

Conditions

• Leukemia, Myeloid, Acute
• Myelodysplastic Syndromes
• Precursor Cell Lymphoblastic Leukemia-Lymphoma

Interventions

Type	Name	Description
DRUG	Azacitidine

Timeline

• Start date: 2013-04-15
• Primary completion: 2018-08-31
• Completion: 2018-12-24
• First posted: 2012-12-11
• Last updated: 2019-10-16
• Results posted: 2019-10-16

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study